Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
| العنوان: | Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease |
|---|---|
| المؤلفون: | Bhatt, Dl, Szarek, M, Pitt, B, Cannon, Cp, Leiter, La, Mcguire, Dk, Lewis, Jb, Riddle, Mc, Inzucchi, Se, Kosiborod, Mn, Cherney, Dzi, Dwyer, Jp, Scirica, Bm, Bailey, Cj, Díaz, R, Ray, Kk, Udell, Ja, Lopes, Rd, Lapuerta, P, Steg, Gabriel, P, Lauro, D |
| المصدر: | Bhatt, D L, Szarek, M, Pitt, B, Cannon, C P, Leiter, L A, McGuire, D K, Lewis, J B, Riddle, M C, Inzucchi, S E, Kosiborod, M N, Cherney, D Z I, Dwyer, J P, Scirica, B M, Bailey, C J, Díaz, R, Ray, K K, Udell, J A, Lopes, R D, Lapuerta, P, Steg, P G & SCORED Investigators 2021, ' Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ', The New England Journal of Medicine, vol. 384, no. 2, pp. 129-139 . https://doi.org/10.1056/NEJMoa2030186Test NEW ENGLAND JOURNAL OF MEDICINE r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, SAXAGLIPTIN, 030204 cardiovascular system & hematology, Saxagliptin, MELLITUS, chemistry.chemical_compound, 0302 clinical medicine, Settore MED/13, Glycosides, 030212 general & internal medicine, 11 Medical and Health Sciences, RISK, SGLT2 INHIBITOR, OUTCOMES, Kidney, EMPAGLIFLOZIN, General Medicine, Middle Aged, Hospitalization, medicine.anatomical_structure, Cardiovascular Diseases, HEART-FAILURE, Diarrhea/chemically induced, Female, OUTPATIENTS, Life Sciences & Biomedicine, Diarrhea, medicine.medical_specialty, SCORED Investigators, Mycoses/etiology, Diabetic ketoacidosis, Renal Insufficiency, Chronic/complications, Glycosides/adverse effects, Diabetic Ketoacidosis, 03 medical and health sciences, Medicine, General & Internal, Sodium-Glucose Transporter 1, Double-Blind Method, General & Internal Medicine, Internal medicine, Diabetes mellitus, medicine, Empagliflozin, Humans, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Aged, Hospitalization/statistics & numerical data, Science & Technology, Diabetic Ketoacidosis/chemically induced, urogenital system, business.industry, MORTALITY, Cardiovascular Diseases/epidemiology, Diabetes Mellitus, Type 2/complications, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, medicine.disease, CARDIOVASCULAR EVENT RATES, Clinical trial, Mycoses, chemistry, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 1/antagonists & inhibitors, Heart failure, business, Kidney disease |
| الوصف: | In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin. Background The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. Methods We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, >= 7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m(2) of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding. Results Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1533-4406 0028-4793 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9705eeadc025b1e0478507d16cdaa4Test https://pure.au.dk/portal/da/publications/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-diseaseTest(6bc50c6b-8a7a-4eea-bd9e-9032680e8b64).html |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5e9705eeadc025b1e0478507d16cdaa4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|